Choi Sangjoon, Park Sujin, Kim Hyunjin, Kang So Young, Ahn Soomin, Kim Kyoung-Mee
Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Korea.
Center of Companion Diagnostics, Samsung Medical Center, Seoul 06351, Korea.
Biomedicines. 2022 Feb 24;10(3):543. doi: 10.3390/biomedicines10030543.
Gastric cancer (GC) remains one of the most common deadly malignancies worldwide. Recently, several targeted therapeutics for treating unresectable or metastatic GC have been developed. Comprehensive characterization of the molecular profile and of the tumor immune microenvironment of GC has allowed researchers to explore promising biomarkers for GC treatment and has enabled a new paradigm in precision-targeted immunotherapy. In this article, we review established and promising new biomarkers relevant in GC, with a focus on their clinical implications, diagnostic methods, and the efficacy of targeted agents.
胃癌（GC）仍然是全球最常见的致命恶性肿瘤之一。最近，已经开发出几种用于治疗不可切除或转移性GC的靶向疗法。对GC的分子特征和肿瘤免疫微环境进行全面表征，使研究人员能够探索有前景的GC治疗生物标志物，并开启了精准靶向免疫治疗的新模式。在本文中，我们综述了与GC相关的已确立和有前景的新生物标志物，重点关注它们的临床意义、诊断方法以及靶向药物的疗效。
